A carregar...
Constraints on the Dominant Mechanism for HIV Viral Dynamics in Patients on Raltegravir
BACKGROUND: Raltegravir is the first publicly released HIV-1 integrase inhibitor. In clinical trials, patients on a raltegravir-based HAART regimen were observed to have 70% less viremia in the second phase-decay of viremia than patients on an efavirenz-based HAART regimen. Because of this accelerat...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2980788/ https://ncbi.nlm.nih.gov/pubmed/19430101 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|